Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Warum der Warren Buffett des Bergbaus alles auf diese Aktie setzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YSP | ISIN: US8730485088 | Ticker-Symbol:
NASDAQ
07.01.25
22:00 Uhr
7,170 US-Dollar
0,000
0,00 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
T STAMP INC Chart 1 Jahr
5-Tage-Chart
T STAMP INC 5-Tage-Chart
GlobeNewswire (Europe)
261 Leser
Artikel bewerten:
(1)

Trust Stamp announces a strategic partnership projected to generate up to $4.3m of revenue receipts in 2025

Finanznachrichten News

Atlanta, GA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered technologies, has announced a strategic transaction with Qenta Inc. ("Qenta"). Under the arrangement, Qenta is spinning its Goldstar KYC technology off into a newly formed subsidiary, QID Technologies LLC ("QID"), with Trust Stamp having a 10% ownership interest in the new entity. In parallel, Trust Stamp has provided a non-exclusive license of its AI-powered identity technologies to QID in return for a single $1m license fee receivable in three installments over Q1 of 2025.

QID is also contracting with Trust Stamp for business development, product development, and product operations for identity and privacy services and solutions in return for monthly service fees starting January 1st, 2025, and capped at $3.6m annually. As Trust Stamp is a 10% equity holder in QID, the projected $3.6m in billed revenue would result in a net cash inflow of $3.3m.

Gareth N. Genner, CEO of the Company, observed, "This strategic transaction brings together Trust Stamp's unique AI-powered identity authentication and tokenization technology, Qenta's global asset tokenization capability, and the power of the QOS permissioned blockchain. The result is a robust identity and asset ecosystem designed to resist threats, including quantum computing, ransomware, and deepfake technologies. From a Trust Stamp perspective, the transaction is immediately accretive in that we have been able to restructure and reallocate existing resources to service this new revenue stream without incurring additional expenses."

Gareth N. Genner further commented, "QID is a perfect fit for our mission of accelerating secure financial and societal inclusion. The partnership allows our AI-powered technology to be deployed in a wider range of large-scale use cases, including national identity programs while providing Trust Stamp with potentially valuable equity participation and offsetting a significant proportion of our operating costs."

About Trust Stamp

Trust Stamp is a global provider of AI-powered software and data transformation services for use in multiple sectors, including banking and finance, regulatory compliance, government, real estate, communications, and humanitarian services. Trust Stamp is located across North America, Europe, Asia, and Africa and trades on the Nasdaq Capital Market (Nasdaq: IDAI). www.truststamp.ai

About Qenta

Qenta Inc. is a comprehensive financial services & technology platform offering asset tokenization, cashless payments, and capital & risk management solutions, uniquely positioned to serve emerging markets. By reducing friction and delivering better access to financial products and services, Qenta Inc. aims to create borderless and democratized financial ecosystems to elevate global businesses and citizens. www.qenta.com

Enquiries

Trust Stamp Email: Shareholders@truststamp.ai

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks

All statements in this release that are not based on historical fact are "forward-looking statements," including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.